FDA 483 - Roslin Cell Therapies Limited - January 21, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of ROSLIN CELL THERAPIES LIMITED in Edinburgh revealed significant deficiencies across multiple areas. Observations included inadequate aseptic gowning during sterile drug product manufacturing, lack of access controls and audit trails for electronic production data, and failures within the quality control unit regarding deviation closure and training documentation. These issues indicate a lack of adherence to GMP requirements for sterile drug production and data integrity.
ID · 0bf97933-396f-4abf-9880-4c5402d1c3b1